Notes in Week 6 - Hypothalamic & Pituitary Pharm

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/14/2025	Continuous release of hormones from the hypothalamus will {{c1::decrease}} tropin release from the pituitary gland
Published	02/14/2025	Tesamorelin and sermorelin are recombinant forms of {{c1::GHRH}}
Published	02/14/2025	Somatropin is a recombinant form of {{c1::growth hormone}}
Published	02/14/2025	Lanreotide and pasireotide are recombinant forms of {{c1::somatostatin}}
Published	02/14/2025	{{c1::Sermorelin::Sermorelin/Tesamorelin}} is indicated in treating growth retardation
Published	02/14/2025	{{c1::Tesamorelin::Sermorelin/Tesamorelin}} is indicated in treating HIV-associated lipodystrophy
Published	02/14/2025	Somatropin can be used to treat HIV-associated {{c1::cachexia}}
Published	02/14/2025	Somatropin can be used to treat {{c1::small bowel syndrome}} especially in patients undergoing total parenteral nutrition
Published	02/14/2025	Somatropin promotes tissue growth and fluid retention in the Eustachian tube, thus increasing the risk of {{c1::otitis media}} in …
Published	02/14/2025	Somatropin promotes tissue growth and fluid retention in the wrist, thus increasing the risk of {{c1::carpal tunnel syndrome}} in adults
Published	02/14/2025	Somatropin increases thyroid metabolism which may lead to {{c1::hypothyroidism}} in certain patients
Published	02/14/2025	Somatropin is contraindicated in critically ill patients and patients with {{c1::malignancy}}
Published	02/14/2025	Pegvisomant antagonizes GH receptors by disrupting {{c1::dimerization}}
Published	02/14/2025	What class of drugs is second-line in the treatment of acromegaly?{{c1::GH antagonists (e.g. pegvisomant)}}
Published	02/14/2025	{{c1::Conivaptan}} is an ADH antagonist that blocks the {{c2::V1a and V2}} receptor
Published	02/14/2025	Pharmacotherapy for nephrogenic diabetes insipidus includes the use of {{c1::diuretics}}
Published	02/14/2025	The V1{{c1::a}} receptor is responsible for vasoconstriction and platelet aggregation
Published	02/14/2025	ADH antagonists (e.g. conivaptan, tolvaptan) have a time-limited use due to risk of {{c1::hepatotoxicity}}
Published	02/14/2025	{{c2::Atosiban}} is an oxytocin-receptor {{c1::antagonist}}
Published	02/14/2025	{{c2::Pitocin}} is an oxytocin-receptor {{c1::agonist}}
Status	Last Update	Fields